IPO: Emcure Pharmaceuticals

Emcure Pharmaceuticals, a generic drug maker, is launching its IPO (initial public offering) on July 3, 2024. Below's a breakdown of the company's strengths, weaknesses, and growth prospects to help investors make an informed decision. In a nutshell Quality : The company's three-year average ROE and ROCE was nearly 24 per cent each between FY22 and FY24. Growth : The company's revenue grew 6.6 per cent per annum during FY22-FY24 but its profit after tax contracted 13.3 per cent per annum during this period. Valuation : Post the IPO, the stock will be valued at a P/E and P/B ratio of 36.1 and 5.1 times, respectively. Overview: Growing expenditure and penetration in the Indian healthcare sector, along with the 'China plus one' strategy will benefit Emcure Pharma in coming years. However, being a generic drug company, it operates in a highly competitive business environment that may hinder its profitability. About Emcure Pharma Incorporated in 1981, Emcure Pharma manufactures off-patent generic medicines, injectables, and active pharmaceutical ingredients (APIs) across various therapeutic areas. The company operates 13 manufacturing facilities across India and supplies its products to 70 countries. India is its largest market and makes up for 48 per cent of its revenue, followed by Europe with a revenue share of 21 per cent and the US with a share of 14 per cent. Strengths of Emcure Pharma Leadership position: Emcure has a strong presence in the domestic market. It is the market leader in the gynaecology and HIV antiviral therapeutics, and is among the top 10 players in five other therapeutic areas in terms of market share. Vertical integration: The company enjoys operational efficiency, thanks to its vertical integration. It manufactures APIs on its own, which are used in production of finished dosages. For distribution, it has established a strong network in the international markets by either developing its own front-end distribution capabilities, or by joining hands with local players and leveraging their distribution network. Weaknesses of Emcure Pharma Intense competition: Emcure manufactures off-patent products that don't have any significant barriers for entering the market. Hence, the company faces severe competition, exposing it to high price erosion. This also impacted its profitability in FY23 and FY24. Strict regulatory requirements: Pharma companies operate in a very strict regulatory environment both in domestic and international markets. The companies are required to follow a long and tedious regulatory process before starting operations or launching new products. Any negative or unfavourable observation from a regulatory body can lead to significant delays in the company's operations. IPO details Total IPO size (Rs cr) 1,952 Offer for sale (Rs cr) 1,152 Fresh issue (Rs cr) 800 Price band (Rs) 960 - 1,008 Subscription dates July 3-5, 2024 Purpose of issue Repayment of debt Post-IPO M-cap (Rs cr) 19,060 Net worth (Rs cr) 3,752 Promoter holding (%) 78.3 Price/earnings ratio (P/E) 36.1